Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis  Sarah-Jane Schramm, Anna E. Campain, Ricenterd A. Scolyer, Yee Hwa Yang, Graham J. Mann  Journal of Investigative Dermatology  Volume 132, Issue 2, Pages 274-283 (February 2012) DOI: 10.1038/jid.2011.305 Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Timeline of selected key events in the evolution of prognostic/predictive signatures in melanoma (in black text) compared with breast cancer (in gray text). *MINDACT (Microarray In Node-negative and 1–3 positive lymph node Disease may Avoid ChemoTherapy) study, a prospective randomized study comparing the MammaPrint 70-gene signature with common clinical–pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0–3 positive nodes. ^Oncotype DX, a 21-gene quantitative RT-PCR (qRT-PCR) assay for formalin-fixed, paraffin-embedded, estrogen receptor (ER)-positive, lymph node–negative breast cancers to predict risk of recurrence. Journal of Investigative Dermatology 2012 132, 274-283DOI: (10.1038/jid.2011.305) Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions